We are delighted to present this press release from Vicore Pharma reporting the interim results of the AIR study investigating the novel angiotensin 2 receptor agonist, C21, in IPF. The results are fantastic and suggest that C21 can actually increase FVC in patients with IPF. This follows on very well from the findings that C21 can reduce the need for oxygen in patients with COVID-19 pneumonitis.
Breathing Matters has been involved with Vicore Pharma and the development of C21 for over 10 years. We are delighted to see the fruits of these labours and are very excited and all set up to recruit our first IPF patient to the AIR study at UCLH. If you are an IPF patient at UCLH and are interested in being recruited to the AIR Study, please speak to your consultant.